**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 62758

**Manuscript Type:** REVIEW

**Molecular alterations in pancreatic tumors**

Visani M *et al*. Molecular alterations in pancreatic tumors

Michela Visani, Giorgia Acquaviva, Antonio De Leo, Viviana Sanza, Lidia Merlo, Thais Maloberti, Alba A Brandes, Enrico Franceschi, Monica Di Battista, Michele Masetti, Elio Jovine, Sirio Fiorino, Annalisa Pession, Giovanni Tallini, Dario de Biase

**Michela Visani, Giorgia Acquaviva, Antonio De Leo, Viviana Sanza, Lidia Merlo, Thais Maloberti, Giovanni Tallini,** Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna–Molecular Diagnostic Unit, Azienda USL di Bologna, Bologna 40138, Italy

**Antonio De Leo, Annalisa Pession, Giovanni Tallini, Dario de Biase,** Division of Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy

**Alba A Brandes, Enrico Franceschi, Monica Di Battista,** Medical Oncology Department, Azienda USL/IRCCS Istituto Delle Scienze Neurologiche di Bologna, Bologna 40139, Italy

**Michele Masetti, Elio Jovine,** Division of Surgery, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40133, Italy

**Sirio Fiorino,** Internal Medicine Unit, Budrio Hospital Azienda USL, Bologna 40133, Italy

**Annalisa Pession, Dario de Biase,** Department of Pharmacy and Biotechnology, University of Bologna, Bologna 40138, Italy

**Author contributions:** de Biase D conceived and designed the study; Visani M, AcquavivaG, De LeoA, SanzaV, MerloL, MalobertiT, FranceschiE, Di BattistaM, MasettiM, Fiorino S and de Biase D performed the literature search and acquisition of the data; BrandesAA, Jovine E, PessionA and TalliniG performed the interpretation and the critical revision of the data; Visani M and de Biase D wrote the manuscript; all authors have read and approved the final manuscript.

**Corresponding author: Dario de Biase, MSc, PhD, Assistant Professor,** Department of Pharmacy and Biotechnology, University of Bologna, viale Ercolani 4/2, Bologna 40138, Italy. dario.debiase@unibo.it

**Received:** January 17, 2021

**Revised:** February 25, 2021

**Accepted:** April 14, 2021

**Published online:** June 7, 2021

**Abstract**

Genetic alterations in pancreatic tumors can usually be classified in: (1) Mutational activation of oncogenes; (2) Inactivation of tumor suppressor genes; and (3) Inactivation of genome maintenance genes controlling the repair of DNA damage. Endoscopic ultrasound-guided fine-needle aspiration has improved pre-operative diagnosis, but the management of patients with a pancreatic lesion is still challenging. Molecular testing could help mainly in solving these “inconclusive” specimens. The introduction of multi-gene analysis approaches, such as next-generation sequencing, has provided a lot of useful information on the molecular characterization of pancreatic tumors. Different types of pancreatic tumors (*e.g.*, pancreatic ductal adenocarcinomas, intraductal papillary mucinous neoplasms, solid pseudopapillary tumors) are characterized by specific molecular alterations. The aim of this review is to summarize the main molecular alterations found in pancreatic tumors.

**Key Words:** Pancreatic tumors; Molecular alterations; Pancreatic ductal adenocarcinomas; Intraductal papillary mucinous neoplasm; Mutations; Molecular markers

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Visani M, Acquaviva G, De Leo A, Sanza V, Merlo L, Maloberti T, Brandes AA, Franceschi E, Di Battista M, Masetti M, Jovine E, Fiorino S, Pession A, Tallini G, de Biase D. Molecular alterations in pancreatic tumors. *World J Gastroenterol* 2021; 27(21): 2710-2726

**URL:** https://www.wjgnet.com/1007-9327/full/v27/i21/0000.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v27.i21.2710

**Core Tip:** To date, in patients with pancreatic cancer there are no targetable molecules for personalized treatment in clinical practice. The introduction of multi-gene analysis approaches, such as massive parallel sequencing, has provided a lot of useful information regarding the molecular characterization of pancreatic tumors. However, a huge amount of data needs to be properly managed to determine the information that is useful and correct. A deeper knowledge of the molecular alterations characterizing pancreatic neoplasms may lead to new potential therapeutic targets for these tumors.

**INTRODUCTION**

Genetic alterations in pancreatic tumors are usually classified in: (1) Tumors with activation of oncogenes (*e.g.*, *KRAS* mutation—more than 90% of pancreatic tumors); (2) Tumors harboring inactivation of tumor suppressor genes (*e.g.*, *p16*/*CDKN2A*, *TP53*, and *SMAD4*); and (3) Tumors with inactivation of genes controlling the repair of DNA damage (*e.g.*, *hMLH1* and *MSH2*)[1].

*KRAS* gene mutations inhibit the ability of KRAS protein to hydrolyze GTP (guanosine-5'-triphosphate), leaving the protein constitutively active, mediating cell survival and differentiation. *KRAS* is the most common marker used for single-gene testing. Its use is strongly limited by the identification of mutations also in low-grade pancreaticobiliary dysplasia or chronic pancreatitis (about 10%)[2-5]. To date, the “The Papanicolaou Society of Cytopathology guidelines” does not encourage testing of *KRAS* in bile duct strictures and solid pancreatic masses as a useful “single-gene” test.

P53 protein is involved in cell-cycle regulation, the apoptotic process, and plays a crucial role in the maintenance of genomic stability. Mutations in the *TP53* gene lead to inactivation of the normal protein function. In the presence of DNA damage, the functional loss of the p53 protein enhances cellular survival, facilitating the accumulation of further genetic mutations[6]. *TP53* is mostly inactivated by single-point mutations[7]. *TP53* gene inactivation is a very common event in pancreatic cancer (50% to 75% of pancreatic cancers harbor *TP53* mutations)[7-9].

*CDKN2A/p16* maps on chromosome 9p and encodes the protein p14ARF, an activator of p53 protein, and p16INK4a protein. This protein inhibits the progression of the cell cycle at the G1-S checkpoint binding of cyclin-dependent kinases (CDKs), as CDK4 and CDK6[10]. *CDKN2A/p16* was the first tumor suppressor gene that was shown to undergo silencing and promoter hypermethylation in pancreatic cancer[11]. The Rb/p16 pathway is down-regulated in most pancreatic cancers, almost all through p16 gene inactivation[11]. Mutations in the *CDKN2A* gene are associated with an increased risk of cancers. Moreover, *CDKN2A* alterations are also frequently observed in cancer cell lines.

*SMAD4/DPC4* gene is located on chromosome 18q and the protein acts in the signal transduction cascade, involving transforming growth factor β (TGF-β). A loss of SMAD4 protein leads to unregulated cellular proliferation[12].

The aim of this review is to summarize the main molecular alterations found in pancreatic tumors, both in solid (*e.g.*, pancreatic ductal adenocarcinoma (PDAC), Table 1) and in cystic neoplasms (*e.g.*, intraductal papillary mucinous neoplasms, IPMN).

**PDAC**

***Wide genome analysis***

According to data obtained by whole-exome sequencing analysis, PDAC harbors an average of about 60 genetic alterations, and most of them are point mutations[1,8,13]. Based on these alterations, 12 cellular pathways genetically altered in pancreatic neoplasia have been identified[8]. Massive sequencing studies carried out on PDACs revealed that alterations may be found in some well-known genes (*e.g.*, *KRAS*, *CDKN2A*, *TP53*, *ARID1A*, *SMAD4*) or in novel genes, that may be involved in DNA damage repair (*e.g.*, *ATM*), chromatin modification (*e.g.*, *EPC1* and *ARID2*), or in neoplastic carcinogenesis (*e.g.*, *KDM6A* and *PREX2*)[14]. Whole-exome sequencing analysis has defined some putative therapeutic targets (*e.g.*, RBM10) associated with longer survival in patients with pancreatic cancers, others associated with improved survival (*e.g.*, KRAS p.Q61H mutation), and others defining sensitivity to target therapies in PDAC models (*e.g*., BRAF mutations as sensitivity markers for treatment with vemurafenib)[15].

An expression analysis study led to the cluster of PDAC in 4 different subtypes: (1) Squamous; (2) Pancreatic progenitor; (3) Immunogenic; and (4) Aberrantly differentiated endocrine exocrine[16]. Also analysis of the structural genomic alterations in PDACs have been classified into four different subtypes: (1) “Stable”, when PDACs contain less than 50 structural variations; (2) “Locally rearranged”, when PDACs exhibit a focal event on one or two chromosomes; (3) “Scattered subtype”, when PDACs show a fewer number of chromosomal damages and less than 200 structural variations; and (4) “Unstable”, when PDACs exhibit more than 200 structural events[17].

***KRAS***

*KRAS* is the most frequently mutated oncogene in pancreatic cancers (> 95%) and the most frequent gene mutated in PDAC (from 70% to 95%)[8,15,18,19]. The acquisition of a *KRAS* mutation represents an early and initiating event in PDACs. However, the low frequency of progression of precursor lesions to PDAC suggests that additional alterations are needed for neoplastic progression[20]. In PDAC, the mutations in *KRAS* are not located only in exon 2, but they have also been found in other exons[14,15,21]. However, the mutations harbored in exon 2 exhibited a similar association with survival, while cases mutated in exon 3 seem to have a remarkably favorable prognosis[15]. Coexistent *KRAS* mutations were detected in the same pancreatic neoplastic mass more frequently than in other tumors[21-23].

*KRAS* analysis may be of particular interest in the case of doubtful or inconclusive diagnoses (*e.g.*, specimens with cytological atypia or acellular specimens). It is well-established that cytopathology together with *KRAS* analysis allows improved diagnosis of PDAC in endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) specimens[24-31]. Finding a *KRAS* mutation in EUS-FNA material may: (1) Indicate that a re-evaluation of the cytopathology report is needed (mainly if doubtful); (2) Indicate a second FNA or surgery[21]; and (3) Lead to a reduction in false-negative diagnoses[32].

A worse prognosis has been observed in patients with tumors harboring coexistent *KRAS* mutations together with TP53 alterations and/or loss of SMAD4 protein[33,34]. KRAS p.G12C variant is a mutation that could be targeted by KRAS-G12C-specific inhibitors[35]. PDAC which also harbors the p.G12C alteration may benefit from this treatment. KRAS-wild type PDACs represent a distinct molecular subtype of pancreatic cancer that could benefit from tailored treatments, including BRAF antagonists and MAPK inhibitors[36].

***TP53***

EUS-FNA sensitivity in the diagnosis of pancreatic malignant lesions can be improved by also implementing the evaluation of the *TP53* gene[37-39]. P53 protein overexpression has been detected in specimens with pancreatic cancer but not in those with chronic pancreatitis. TP53 alterations have been detected in 50%-75% of PDACs. Combining the evaluation of p53 protein expression with histological examination improves the sensitivity of diagnosis of pancreatic cancers, with a high specificity[37,38]. The sensitivity of EUS-FNA in the diagnosis of PDAC is further improved by combining p53 and Ki67 staining[38].

The combination of p53 and CA19.9 increases the sensitivity of cytology but it can negatively affect the specificity[39]. A worse patient prognosis has been correlated with loss of p53 protein, mainly if p53 loss is combined with KRAS alterations and loss of SMAD4 protein expression[33,34]. In a recent study based on next-generation sequencing (NGS) results from the CONKO-001 phase III trial, it has been demonstrated that patients with *TP53* mutated PDAC tumors benefit from adjuvant gemcitabine treatment[40].

***SMAD4***

Approximately 50% of pancreatic cancers show SMAD4 protein inactivation, due to homozygous deletion and intragenic mutations[10,41-43]. Loss of SMAD4 generally occurs late in pancreatic carcinogenesis, and it has been frequently observed in pancreatic adenocarcinomas, but not in extra-pancreatic lesions[44]. In reactive and inflammatory diseases of the pancreas (*e.g.*, chronic pancreatitis) SMAD4 activity is usually preserved. Loss of SMAD4 protein has also been linked with an increased risk of developing metastases and worse prognosis[33,34,43,45,46]. In PDAC, *SMAD4* mutations lead to the prevention of the normal transduction of TGF-β signals; TGF-β inhibitor has shown efficacy in a preclinical investigation[47].

A study by Hsieh *et al*[48] demonstrated that SMAD4 deficiency in PDAC cells led to higher sensitivity to gemcitabine. On the contrary, *SMAD4* mutated cells were sensitive to gemcitabine similar to that in cells with wild-type SMAD4[48]. These data suggest that the *SMAD4* copy number may be a therapeutic marker for PDAC treatment with gemcitabine[49]. In this study, it was observed that SMAD4 deficiency led to upregulation of cell cycle-related genes, such as CDK1, with consequent higher sensitivity to other agents modulating the cell cycle such as clofarabine, cytarabine, darinaparsin, and olaparib[48,49].

***CDKN2A***

More than 95% of sporadic pancreatic carcinomas harbor a *CDKN2A* gene inactivation due to intragenic mutation, usually coupled with the loss of the other allele, promoter hypermethylation, or homozygous deletion of both alleles[50-52]. *CDKN2A* is involved in familial pancreatic cancer, although *CDKN2A* germline mutations in patients with pancreatic cancer occur rarely (0.6%)[53,54]. Patients harboring *CDKN2A* mutations are more likely to report a family history of pancreatic cancer than those without *CDKN2A* alterations[54]. Surveillance protocols from age 40 are recommended for *CDKN2A* mutation carriers[55].

Decreased expression of p16 protein has been associated with a tendency for the tumor to be larger than in those with normal p16 expression levels. Pancreatic neoplasms with loss of p16 expression, due to mutations and/or promoter hypermethylation, are significantly larger. Moreover, the survival period in these patients was significantly shorter when compared to those with a pancreatic tumor characterized by intact p16 functions[33,56,57]. CDK4/6 is a potential target in CDKN2A-deficient tumors and the efficacy of CDK4 inhibitors has been confirmed in PDAC preclinical models[58].

***BRCA1-2***

Alterations in the BRCA pathway and defects in DNA maintenance (such as genomic instability and the BRCA mutational signature) may have implications for the therapeutic selection of patients with pancreatic tumors[17]. *BRCA1/2* mutation frequencies range from 5% to 10%, and BRCA alterations have been detected both in sporadic and familial PDAC[1,59]. Patients with PDAC harboring germline *BRCA1* or *BRCA2* mutations showed a longer progression-free survival if treated with a PARP inhibitor[60,61]. According to the recommendation from the International Cancer of the Pancreas Screening Consortium, for *BRCA1* a consensus of 69.9% was reached for recommending that *BRCA1* mutation carriers undergo surveillance, whereas no consensus was reached on family history criteria for *BRCA1* mutation carriers[55]. For carriers of *BRCA2* mutations, the consensus (agreement of 93%) was to recommend surveillance for mutation carriers who have a blood relative with pancreatic cancer[55]. For *BRCA2* mutation carriers with a germline variant (deleterious), the recommended age to initiate surveillance is generally 50 years[55]. With regard to the surveillance protocols for high-risk individuals, the consensus is that pancreatic imaging with magnetic resonance imaging (MRI)/magnetic retrograde cholangiopancreatography and/or EUS should be the first-line test for pancreatic surveillance[55]. Pancreatic computed tomography is reserved for individuals unable to undergo MRI or EUS[55].

***Other alterations***

Even if uncommon, MSI/dMMR (Microsatellite Instability/defective DNA mismatch repair) has been described in about 1%-2% of PDAC[62,63]. PDACs with MSI are usually associated with medullary histology and are rarely mutated in *KRAS* or *TP53* genes[62,64]. National Comprehensive Cancer Network (NCCN) guidelines recommend the MSI and MMR tests in locally advanced and metastatic pancreatic carcinomas[65]. NCCN recommends the treatment of PDAC with the PD-1 (programmed cell death-1) inhibitor, Pembrolizumab, only in those patients with MSI-H (high-MSI) or dMMR advanced/metastatic pancreatic cancer[65].

*BRAF* mutations are an uncommon event in PDAC[1]. Some evidence suggests that patients with pancreas tumors harboring *BRAFV600E* mutations may benefit from treatment with RAF-MEK-targeted therapy[66].

The *MGMT* promoter can be hypermethylated in PDAC[34,67]. In 1998, treatment with temozolomide in advanced pancreatic cancer has been tried in a phase II study, but no relevant clinical response was observed[68]. *ARID1A* oncosuppressor protein deficiency was significantly associated with poor outcome in PDAC patients[15]. Amplifications and copy-number gains of oncogenes such as *ERBB2*, *MET*, and *FGFR1* may be detected in pancreatic tumors[17]. The inactivation of several genes (*e.g.*, *ROBO1*, *ROBO2*, *SLIT2*, and *RNF43*) leads to an aberrant WNT (Wingless-related integration site) signaling[15,17]. Unresectable non-metastatic pancreatic carcinomas may also harbor mutations in *GRM8* and *TRIM33* genes[69], while only a small fraction (approximately 5%) of pancreatic adenocarcinomas showed Cyclin E overexpression[70]. Different to solid pseudopapillary neoplasia (SPN), *CTNNB1* mutations are uncommon in PDAC[15,71]. In PDAC, the frequency of *NTRK* (neurotrophic tropomyosin receptor kinase) fusion is very low (about 0.3%), but clinical trials revealed that the selective TRK (tropomyosin receptor kinase) inhibitors are also effective in PDAC harboring *NTRK* rearrangement[58]. NCCN guidelines suggest the use of a TRK inhibitor in *NTRK* gene fusion-positive advanced/metastatic pancreatic cancer[61,65].

Organoids are a preclinical model that is becoming increasingly important for studying tumor behavior because they can simulate metastases, microtumors, and the tumor microenvironment better than “classical” monolayer culture systems[72]. An interesting preclinical model for the study of PDAC is the set-up of three-dimensional (3D)-tumoroids *in vitro* culture systems[72-78]. These organoids can also be generated from a resected PDAC and are amenable to therapeutic screening as well as genetic and biochemical perturbation[77]. In a study by Boj *et al*[76], organoids derived from murine and human PDAC generated lesions similar to pancreatic intraepithelial neoplasia (PanIN) and progressed to invasive PDAC. Intriguingly, the expression of mutated KRAS protein (KRASG12D) in PDAC organoids was sufficient to induce a preinvasive neoplasm[76]. PDAC tumoroid cultures retain the capacity to maintain tumor stroma and characteristics of the primary tumor including the long-term (> 44 d) production of CEA (carcinoembryonic antigen) and CA19-9 (carbohydrate antigen 19-9)[74]. This 3D cell culture model of PDAC would help the diagnostics, investigation of genetic drivers, and identification of novel therapeutic targets[72]. Moreover, this culture could also allow clarification on how the immunosuppressive mechanism affects the growth and stasis of tumors[74]. Moreover, another important aspect is that organoids are suitable for storage in biobanks and used for further research, ensuring access to relevant sample numbers[78].

**Cystic Pancreatic Tumors**

***IPMN***

*KRAS* mutations are harbored by over 90% of low-grade PanIN[79], and mutant *KRAS* is sufficient to initiate the development of PanINs and IPMNs[20,80-83] (Table 2).

The distinction between IPMNs and mucinous cystic neoplasms (MCNs) from non-neoplastic pancreatic cysts may be helped by analysis of pancreatic cyst fluid. In fact, a *KRAS* mutation is highly specific for mucinous differentiation, but not for identifying MCNs[84]. *KRAS* alterations have a very high specificity but low sensitivity for MCNs and IPMNs (approximately 15% and 70%, respectively). If *KRAS* analysis is combined with that of *GNAS*, the sensitivity increases[85,86]. The differential diagnosis of cystic mucinous lesions (IPMN and MCN), mainly when the pre-operative cytology is non-diagnostic or when the CEA cyst fluid levels are indeterminate, may be helped by the analysis of *KRAS* and Loss-of-Heterozygosity (LOH)[87].

IPMNs rarely harbor mutations in the *TP53* gene (approximately 10%). The overexpression of *TP53* was more commonly observed in IPMNs of the pancreatobiliary type with invasion[88]. In a cohort of IPMN patients, the overexpression of TP53, together with loss of function of SMAD4, was strongly associated with patient survival[88]. In IPMNs, SMAD4 loss of function was rarely detected; SMAD4 loss is more common in IPMNs of the pancreatobiliary type with invasion[88].

The *GNAS* gene encodes the α-subunit of the stimulatory G-protein (Gαs). This subunit regulates the adenylate cyclase activity through Gαs-coupled receptors. Alterations in GNAS may determine the characteristic IPMN phenotype[89]. *GNAS* activating mutations are reported prevalently in IPMN (approximately 40%-60%)[85,88,90-92] and invasive pancreatic cancers, only if arising in association with an IPMN[79,93]. In the majority of IPMNs (approximately 90%), at least one of the *KRAS* or *GNAS* genes harbor mutations[94], and in about half of IPMN (approximately 40%), a *GNAS* alteration coexists with a *KRAS* mutation[90]. The combination of *KRAS* and *GNAS* mutations helps in distinguishing between a serous cystic neoplasm (SCN) and an IPMN with high sensitivity and specificity. In fact, if most IPMNs have a *GNAS* and/or a *KRAS* alteration, no SCNs harbor either mutation. Besides, detecting a mutation in the *GNAS* gene in cyst fluid may help to distinguish IPMNs from MCNs[95].

*RNF43* mutation frequency in IPMN is about 25%, ranging from 10% to 75%[93,96]. These mutations are often inactivating alterations and are found in association with LOH.

*CDKN2A/p16* inactivating mutations have also been found in IPMNs with high-grade dysplasia, other than in pancreatic adenocarcinoma[97].

Germline mutations of *STK11/LKB1* genes have been associated with IPMNs and invasive pancreatic cancer[98,99]. Besides, somatic mutations of *STK11/LKB1* are observed in about 5% of patients with sporadic IPMNs and pancreatic cancers[98,99].

A high amount of DNA and high-amplitude mutations in the pancreatic cyst fluid may be indicators of malignancy, helping to identifying malignant cystic lesions[86].

The use of NGS in pancreatic cyst fluid allows high sensitivity and specificity in classifying pancreatic cancers, mainly for the diagnosis of IPMN with advanced neoplasia[100].

***MCN***

MCNs harbor alterations also commonly found in PDAC. MCNs frequently have *KRAS* gene mutations, mainly in MCNs with high-grade dysplasia[101]. The diagnosis of mucinous cysts may be helped by the presence of a *KRAS* mutation in cyst fluid[86]. p16/CDKN2A expression is altered in MCN, even if in a lower percentage (about 15%) if compared to that of PDAC[102]. P53 has been reported with aberrant expression in MCN with high-grade dysplasia[103]. *TP53* alterations are often associated with aggressiveness and seem to be involved in progression to PDAC[92]. Mutations of *RNF43* have been reported in MCN[92]. *PIK3CA* alterations were described with very low frequency in MCN and in association with high-grade dysplasia and invasive adenocarcinoma[104]. As in IPMN, no *VHL* mutations were detected in MCN[92], but, different to IPMN, the *GNAS* gene is not mutated in MCN[96]. The LOH of *Dpc4*/*Smad4* contributes to MCN progression in mice with *KRAS-G12D* mutation[105], confirming that the *SMAD4* gene acts as a PDAC tumor suppressor[106]. Whole-exome sequencing performed on a cohort of MCN revealed that the tumors harbored about 16 somatic mutations per tumor, lower than the number of mutations observed in IPMN (about 27 per tumor)[92].

***SCN***

*VHL* mutations are frequently reported in SCN (from 40% up to 60% of cases)[100,107]. SCNs usually do not harbor alterations in genes frequently mutated in IPMN, or MCN (*i.e.*, *KRAS*, *GNAS*, *TP53*), helping to distinguish SCNs from the other mucinous neoplasia[100,108]. The lack of *CTNNB1* mutations allows the differentiation of SCN from SPN. Moreover, SCNs do not harbor mutations in genes frequently altered in neuroendocrine pancreatic tumors[109]. Whole exome sequencing analysis performed on a cohort of eight SCNs revealed that almost all tumors harbored a LOH on chromosome 3p[92]. An average of only 10 non-synonymous somatic mutations was detected in SCNs[92], far less than the average observed in PDAC.

**Other pancreatic tumors**

***SPN***

The *CTNNB1* gene (codons from 32 to 37) encodes for a region that plays a crucial role in the regulation of the β-catenin protein[110,111]. Alterations within this *CTNNB1* region usually block β-catenin phosphorylation, inhibiting degradation of the protein[112]. *CTNNB1* mutations are characteristic of pancreatic SPN[71,113,114]. Different to PDAC, SPNs are not mutated in *KRAS*, *TP53*, or *SMAD4* genes, and *CTNNB1* mutations are the main molecular alteration detected[92]. DNA array CGH (comparative genomic hybridization) performed on a pediatric case of SPN revealed a loss in chromosome band 11p15.5, a chromosomal region encoding for the *HRAS* gene[115]. As suggested by Selenica *et al*[116], even if inhibition of the Wnt pathway may be an intuitive therapeutic option for this disease, the evidence that clinically advanced Wnt pathway inhibitors target components upstreaming β-catenin activity is a clear limitation. For this reason, future drugs should be designed to target the β-catenin protein directly[116] (Table 3).

***Pancreatic neuroendocrine tumors***

Pancreatic neuroendocrine tumors (PanNETs) show a distinct landscape of molecular alterations if compared to the other pancreatic tumors. The mutation frequency in PanNET was lower than that observed in poorly differentiated neuroendocrine carcinomas (45% and 83%, respectively)[117], and the incidence of mutations was higher in PanNET with a high risk of progression than those with low risk[117]. *MEN1* alterations (both mutations and LOH) have been found in up to 70% of PanNETs and have been associated with a better prognosis[118,119]. PanNETs harbor alterations in those genes involved in the chromatin remodeling complex, such as loss of ATRX and DAXX proteins expression[118]. Mutations in the mTOR (mammalian target of rapamycin) pathway genes (*e.g.*, *PIK3CA*, *PTEN*, and *TSC2*) have been detected in PanNET[118]. For example, *PTEN* and *TSC2* genes have been observed as inactivating in primary PanNET and their low protein levels were associated with shorter overall and disease-free survival[120]. *VHL* inactivation, due to deletion or methylation, was also observed in up to 25% of PanNETs[121,122].

***Acinar cell carcinomas***

Activating mutations in *CTNNB1* and inactivating mutations in *APC* genes have been observed in up to 25% of acinar cell carcinomas (ACCs). *KRAS* mutations are an uncommon event in this type of neoplasia[123]. Nevertheless, *TP53* mutations were also found only in a low fraction of ACCs[123-125], deletion of the *TP53* region (chromosome band 17p13.1) was detected by FISH in about half of a cohort of 54 ACCs[125]. Alterations found in IPMN (*e.g.*, *GNAS* and *RNF43*) or in PanNET (*e.g.*, *MEN1*) were rarely found in ACC[126] A genome-wide analysis performed on ACCs revealed a median number of 137 point mutations per tumor and *COL12A1*, *FRY*, *FRYL*, and *PLB1* were the most frequently mutated genes[124]. Intriguingly, a genome-wide analysis identified no recurrent point mutations in ACCs[124]. Microsatellite instability was detected in a fraction of ACC ranging from 7% to 14% of cases[127]. ACC with MSI did not exhibit distinct morphological or clinical features[128].

**CONCLUSION**

To date, there are no targetable molecules available for personalized patient treatment of pancreatic tumors in clinical practice, as stated by the current European Society for Medical Oncology (ESMO) guidelines[129]. EUS-FNA has improved pre-operative diagnosis[130-132], but the management of patients with a pancreatic lesion is still challenging. In fact, in a subset of cases, such as lesions with atypical/suspicious cytopathologic features, the pre-operative diagnosis remains inconclusive[133]. Performing a molecular characterization could help mainly in solving these “inconclusive” specimens. The introduction of multi-gene analysis approaches, such as NGS, has provided a lot of useful information regarding the molecular characterization of pancreatic tumors[134]. EUS-FNAC (FNA cytology) is a useful diagnostic tool for pancreatic lesions[135] and molecular analysis can be successfully performed on cytological smears[21]. However, it has becoming increasingly crucial to have sufficient material for histological, immunohistochemical, and molecular characterization. Pancreatic FNAB (FNA biopsy) provides enough material to allow proper histological assessment, immunostaining, and molecular techniques [*e.g.*, NGS, digital polymerase chain reaction (PCR)][136-138].

A huge amount of data needs to be properly managed to determine the information that is useful and correct[139]. The recent ESMO guidelines have outlined their indications for the use of NGS in the characterization of metastatic cancers. As regards PDAC, it is not currently recommended to perform multigene NGS in daily practice[140]. However, ESMO encourages multigene sequencing in order to get access to innovative drugs. Moreover, NGS can be an alternative technique to PCR-based assays if it is not associated with extra cost for the public health care system if the patient is informed about the putative benefits of this analysis[140]. In conclusion, a deeper knowledge of the molecular alterations characterizing pancreatic neoplasms may lead to new potential therapeutic targets for these tumors.

**REFERENCES**

1 **Cancer Genome Atlas Research Network**. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. *Cancer Cell* 2017; **32**: 185-203.e13 [PMID: 28810144 DOI: 10.1016/j.ccell.2017.07.007]

2 **Layfield LJ**, Ehya H, Filie AC, Hruban RH, Jhala N, Joseph L, Vielh P, Pitman MB; Papanicolaou Society of Cytopathology. Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: the Papanicolaou Society of Cytopathology guidelines for pancreatobiliary cytology. *Diagn Cytopathol* 2014; **42**: 351-362 [PMID: 24639398 DOI: 10.1002/dc.23093]

3 **Lüttges J**, Reinecke-Lüthge A, Möllmann B, Menke MA, Clemens A, Klimpfinger M, Sipos B, Klöppel G. Duct changes and K-ras mutations in the disease-free pancreas: analysis of type, age relation and spatial distribution. *Virchows Arch* 1999; **435**: 461-468 [PMID: 10592048 DOI: 10.1007/s004280050428]

4 **Löhr M**, Klöppel G, Maisonneuve P, Lowenfels AB, Lüttges J. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. *Neoplasia* 2005; **7**: 17-23 [PMID: 15720814 DOI: 10.1593/neo.04445]

5 **Löhr M**, Maisonneuve P, Lowenfels AB. K-Ras mutations and benign pancreatic disease. *Int J Pancreatol* 2000; **27**: 93-103 [PMID: 10862508 DOI: 10.1385/IJGC:27:2:093]

6 **Vogelstein B**, Kinzler KW. Cancer genes and the pathways they control. *Nat Med* 2004; **10**: 789-799 [PMID: 15286780 DOI: 10.1038/nm1087]

7 **Forbes SA**, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, Kok CY, Jia M, De T, Teague JW, Stratton MR, McDermott U, Campbell PJ. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. *Nucleic Acids Res* 2015; **43**: D805-D811 [PMID: 25355519 DOI: 10.1093/nar/gku1075]

8 **Jones S**, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* 2008; **321**: 1801-1806 [PMID: 18772397 DOI: 10.1126/science.1164368]

9 **Scarpa A**, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, Hirohashi S. Pancreatic adenocarcinomas frequently show p53 gene mutations. *Am J Pathol* 1993; **142**: 1534-1543 [PMID: 8494051]

10 **Maitra A**, Hruban RH. Pancreatic cancer. *Annu Rev Pathol* 2008; **3**: 157-188 [PMID: 18039136 DOI: 10.1146/annurev.pathmechdis.3.121806.154305]

11 **Schutte M**, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE, Herman JG. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. *Cancer Res* 1997; **57**: 3126-3130 [PMID: 9242437]

12 **Siegel PM**, Massagué J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. *Nat Rev Cancer* 2003; **3**: 807-821 [PMID: 14557817 DOI: 10.1038/nrc1208]

13 **Wang L**, Tsutsumi S, Kawaguchi T, Nagasaki K, Tatsuno K, Yamamoto S, Sang F, Sonoda K, Sugawara M, Saiura A, Hirono S, Yamaue H, Miki Y, Isomura M, Totoki Y, Nagae G, Isagawa T, Ueda H, Murayama-Hosokawa S, Shibata T, Sakamoto H, Kanai Y, Kaneda A, Noda T, Aburatani H. Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. *Genome Res* 2012; **22**: 208-219 [PMID: 22156295 DOI: 10.1101/gr.123109.111]

14 **Biankin AV**, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead RS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, Samra JS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N; Australian Pancreatic Cancer Genome Initiative, Kakkar N, Zhao F, Wu YQ, Wang M, Muzny DM, Fisher WE, Brunicardi FC, Hodges SE, Reid JG, Drummond J, Chang K, Han Y, Lewis LR, Dinh H, Buhay CJ, Beck T, Timms L, Sam M, Begley K, Brown A, Pai D, Panchal A, Buchner N, De Borja R, Denroche RE, Yung CK, Serra S, Onetto N, Mukhopadhyay D, Tsao MS, Shaw PA, Petersen GM, Gallinger S, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Capelli P, Corbo V, Scardoni M, Tortora G, Tempero MA, Mann KM, Jenkins NA, Perez-Mancera PA, Adams DJ, Largaespada DA, Wessels LF, Rust AG, Stein LD, Tuveson DA, Copeland NG, Musgrove EA, Scarpa A, Eshleman JR, Hudson TJ, Sutherland RL, Wheeler DA, Pearson JV, McPherson JD, Gibbs RA, Grimmond SM. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature* 2012; **491**: 399-405 [PMID: 23103869 DOI: 10.1038/nature11547]

15 **Witkiewicz AK**, McMillan EA, Balaji U, Baek G, Lin WC, Mansour J, Mollaee M, Wagner KU, Koduru P, Yopp A, Choti MA, Yeo CJ, McCue P, White MA, Knudsen ES. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. *Nat Commun* 2015; **6**: 6744 [PMID: 25855536 DOI: 10.1038/ncomms7744]

16 **Bailey P**, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, Nourse C, Murtaugh LC, Harliwong I, Idrisoglu S, Manning S, Nourbakhsh E, Wani S, Fink L, Holmes O, Chin V, Anderson MJ, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Xu Q, Wilson PJ, Cloonan N, Kassahn KS, Taylor D, Quek K, Robertson A, Pantano L, Mincarelli L, Sanchez LN, Evers L, Wu J, Pinese M, Cowley MJ, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chantrill LA, Mawson A, Humphris J, Chou A, Pajic M, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Lovell JA, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Moran-Jones K, Jamieson NB, Graham JS, Duthie F, Oien K, Hair J, Grützmann R, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Rusev B, Capelli P, Salvia R, Tortora G, Mukhopadhyay D, Petersen GM; Australian Pancreatic Cancer Genome Initiative, Munzy DM, Fisher WE, Karim SA, Eshleman JR, Hruban RH, Pilarsky C, Morton JP, Sansom OJ, Scarpa A, Musgrove EA, Bailey UM, Hofmann O, Sutherland RL, Wheeler DA, Gill AJ, Gibbs RA, Pearson JV, Waddell N, Biankin AV, Grimmond SM. Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature* 2016; **531**: 47-52 [PMID: 26909576 DOI: 10.1038/nature16965]

17 **Waddell N**, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G, Tempero MA; Australian Pancreatic Cancer Genome Initiative, Gill AJ, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Pearson JV, Biankin AV, Grimmond SM. Whole genomes redefine the mutational landscape of pancreatic cancer. *Nature* 2015; **518**: 495-501 [PMID: 25719666 DOI: 10.1038/nature14169]

18 **Hruban RH**, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. *Am J Pathol* 1993; **143**: 545-554 [PMID: 8342602]

19 **Aung KL**, Fischer SE, Denroche RE, Jang GH, Dodd A, Creighton S, Southwood B, Liang SB, Chadwick D, Zhang A, O'Kane GM, Albaba H, Moura S, Grant RC, Miller JK, Mbabaali F, Pasternack D, Lungu IM, Bartlett JMS, Ghai S, Lemire M, Holter S, Connor AA, Moffitt RA, Yeh JJ, Timms L, Krzyzanowski PM, Dhani N, Hedley D, Notta F, Wilson JM, Moore MJ, Gallinger S, Knox JJ. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. *Clin Cancer Res* 2018; **24**: 1344-1354 [PMID: 29288237 DOI: 10.1158/1078-0432.CCR-17-2994]

20 **Morris JP 4th**, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. *Nat Rev Cancer* 2010; **10**: 683-695 [PMID: 20814421 DOI: 10.1038/nrc2899]

21 **de Biase D**, Visani M, Baccarini P, Polifemo AM, Maimone A, Fornelli A, Giuliani A, Zanini N, Fabbri C, Pession A, Tallini G. Next generation sequencing improves the accuracy of KRAS mutation analysis in endoscopic ultrasound fine needle aspiration pancreatic lesions. *PLoS One* 2014; **9**: e87651 [PMID: 24504548 DOI: 10.1371/journal.pone.0087651]

22 **Gormally E**, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. *Mutat Res* 2007; **635**: 105-117 [PMID: 17257890 DOI: 10.1016/j.mrrev.2006.11.002]

23 **Visani M**, de Biase D, Baccarini P, Fabbri C, Polifemo AM, Zanini N, Pession A, Tallini G. Multiple KRAS mutations in pancreatic adenocarcinoma: molecular features of neoplastic clones indicate the selection of divergent populations of tumor cells. *Int J Surg Pathol* 2013; **21**: 546-552 [PMID: 23426962 DOI: 10.1177/1066896912475073]

24 **Bournet B**, Souque A, Senesse P, Assenat E, Barthet M, Lesavre N, Aubert A, O'Toole D, Hammel P, Levy P, Ruszniewski P, Bouisson M, Escourrou J, Cordelier P, Buscail L. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis. *Endoscopy* 2009; **41**: 552-557 [PMID: 19533561 DOI: 10.1055/s-0029-1214717]

25 **Bournet B**, Selves J, Grand D, Danjoux M, Hanoun N, Cordelier P, Buscail L. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic cancer. *J Clin Gastroenterol* 2015; **49**: 50-56 [PMID: 24798941 DOI: 10.1097/MCG.0000000000000053]

26 **Ginestà MM**, Mora J, Mayor R, Farré A, Peinado MA, Busquets J, Serrano T, Capellá G, Fabregat J. Genetic and epigenetic markers in the evaluation of pancreatic masses. *J Clin Pathol* 2013; **66**: 192-197 [PMID: 23135349 DOI: 10.1136/jclinpath-2012-201123]

27 **Maluf-Filho F**, Kumar A, Gerhardt R, Kubrusly M, Sakai P, Hondo F, Matuguma SE, Artifon E, Monteiro da Cunha JE, César Machado MC, Ishioka S, Forero E. Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass. *J Clin Gastroenterol* 2007; **41**: 906-910 [PMID: 18090159 DOI: 10.1097/MCG.0b013e31805905e9]

28 **Ogura T**, Yamao K, Sawaki A, Mizuno N, Hara K, Hijioka S, Niwa Y, Tajika M, Kondo S, Shimizu Y, Bhatia V, Higuchi K, Hosoda W, Yatabe Y. Clinical impact of K-ras mutation analysis in EUS-guided FNA specimens from pancreatic masses. *Gastrointest Endosc* 2012; **75**: 769-774 [PMID: 22284089 DOI: 10.1016/j.gie.2011.11.012]

29 **Pellisé M**, Castells A, Ginès A, Solé M, Mora J, Castellví-Bel S, Rodríguez-Moranta F, Fernàndez-Esparrach G, Llach J, Bordas JM, Navarro S, Piqué JM. Clinical usefulness of KRAS mutational analysis in the diagnosis of pancreatic adenocarcinoma by means of endosonography-guided fine-needle aspiration biopsy. *Aliment Pharmacol Ther* 2003; **17**: 1299-1307 [PMID: 12755843 DOI: 10.1046/j.1365-2036.2003.01579.x]

30 **Tada M**, Komatsu Y, Kawabe T, Sasahira N, Isayama H, Toda N, Shiratori Y, Omata M. Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor. *Am J Gastroenterol* 2002; **97**: 2263-2270 [PMID: 12358243 DOI: 10.1111/j.1572-0241.2002.05980.x]

31 **Takahashi K**, Yamao K, Okubo K, Sawaki A, Mizuno N, Ashida R, Koshikawa T, Ueyama Y, Kasugai K, Hase S, Kakumu S. Differential diagnosis of pancreatic cancer and focal pancreatitis by using EUS-guided FNA. *Gastrointest Endosc* 2005; **61**: 76-79 [PMID: 15672060 DOI: 10.1016/s0016-5107(04)02224-2]

32 **Bournet B**, Gayral M, Torrisani J, Selves J, Cordelier P, Buscail L. Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer. *World J Gastroenterol* 2014; **20**: 10758-10768 [PMID: 25152579 DOI: 10.3748/wjg.v20.i31.10758]

33 **Oshima M**, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y, Yachida S. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. *Ann Surg* 2013; **258**: 336-346 [PMID: 23470568 DOI: 10.1097/SLA.0b013e3182827a65]

34 **Masetti M**, Acquaviva G, Visani M, Tallini G, Fornelli A, Ragazzi M, Vasuri F, Grifoni D, Di Giacomo S, Fiorino S, Lombardi R, Tuminati D, Ravaioli M, Fabbri C, Bacchi-Reggiani ML, Pession A, Jovine E, de Biase D. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. *Cancer Biomark* 2018; **21**: 323-334 [PMID: 29103024 DOI: 10.3233/CBM-170464]

35 **Gillson J**, Ramaswamy Y, Singh G, Gorfe AA, Pavlakis N, Samra J, Mittal A, Sahni S. Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy? *Cancers (Basel)* 2020; **12** [PMID: 32456277 DOI: 10.3390/cancers12051341]

36 **Luchini C**, Paolino G, Mattiolo P, Piredda ML, Cavaliere A, Gaule M, Melisi D, Salvia R, Malleo G, Shin JI, Cargnin S, Terrazzino S, Lawlor RT, Milella M, Scarpa A. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. *J Exp Clin Cancer Res* 2020; **39**: 227 [PMID: 33115526 DOI: 10.1186/s13046-020-01732-6]

37 **Itoi T**, Takei K, Sofuni A, Itokawa F, Tsuchiya T, Kurihara T, Nakamura K, Moriyasu F, Tsuchida A, Kasuya K. Immunohistochemical analysis of p53 and MIB-1 in tissue specimens obtained from endoscopic ultrasonography-guided fine needle aspiration biopsy for the diagnosis of solid pancreatic masses. *Oncol Rep* 2005; **13**: 229-234 [PMID: 15643503]

38 **Jahng AW**, Reicher S, Chung D, Varela D, Chhablani R, Dev A, Pham B, Nieto J, Venegas RJ, French SW, Stabile BE, Eysselein VE. Staining for p53 and Ki-67 increases the sensitivity of EUS-FNA to detect pancreatic malignancy. *World J Gastrointest Endosc* 2010; **2**: 362-368 [PMID: 21173913 DOI: 10.4253/wjge.v2.i11.362]

39 **Mu DQ**, Wang GF, Peng SY. p53 protein expression and CA19.9 values in differential cytological diagnosis of pancreatic cancer complicated with chronic pancreatitis and chronic pancreatitis. *World J Gastroenterol* 2003; **9**: 1815-1818 [PMID: 12918127 DOI: 10.3748/wjg.v9.i8.1815]

40 **Sinn M**, Sinn BV, Treue D, Keilholz U, Damm F, Schmuck R, Lohneis P, Klauschen F, Striefler JK, Bahra M, Bläker H, Bischoff S, Pelzer U, Oettle H, Riess H, Budczies J, Denkert C. *TP53* Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial. *Clin Cancer Res* 2020; **26**: 3732-3739 [PMID: 32234756 DOI: 10.1158/1078-0432.CCR-19-3034]

41 **Iacobuzio-Donahue CA**, Wilentz RE, Argani P, Yeo CJ, Cameron JL, Kern SE, Hruban RH. Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression. *Am J Surg Pathol* 2000; **24**: 1544-1548 [PMID: 11075857 DOI: 10.1097/00000478-200011000-00011]

42 **Hahn SA**, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. *Science* 1996; **271**: 350-353 [PMID: 8553070 DOI: 10.1126/science.271.5247.350]

43 **Tascilar M**, Skinner HG, Rosty C, Sohn T, Wilentz RE, Offerhaus GJ, Adsay V, Abrams RA, Cameron JL, Kern SE, Yeo CJ, Hruban RH, Goggins M. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. *Clin Cancer Res* 2001; **7**: 4115-4121 [PMID: 11751510]

44 **Schutte M**, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, Sidransky D, Casero RA Jr, Meltzer PS, Hahn SA, Kern SE. DPC4 gene in various tumor types. *Cancer Res* 1996; **56**: 2527-2530 [PMID: 8653691]

45 **Blackford A**, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Cameron JL, Olino K, Schulick R, Winter J, Herman JM, Laheru D, Klein AP, Vogelstein B, Kinzler KW, Velculescu VE, Hruban RH. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. *Clin Cancer Res* 2009; **15**: 4674-4679 [PMID: 19584151 DOI: 10.1158/1078-0432.CCR-09-0227]

46 **Singh P**, Srinivasan R, Wig JD. SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma. *Pancreas* 2012; **41**: 541-546 [PMID: 22504380 DOI: 10.1097/MPA.0b013e318247d6af]

47 **Shi L**, Sheng J, Wang M, Luo H, Zhu J, Zhang B, Liu Z, Yang X. Combination Therapy of TGF-β Blockade and Commensal-derived Probiotics Provides Enhanced Antitumor Immune Response and Tumor Suppression. *Theranostics* 2019; **9**: 4115-4129 [PMID: 31281535 DOI: 10.7150/thno.35131]

48 **Hsieh YY**, Liu TP, Chou CJ, Chen HY, Lee KH, Yang PM. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma. *Genes (Basel)* 2019; **10** [PMID: 31569425 DOI: 10.3390/genes10100766]

49 **Dardare J**, Witz A, Merlin JL, Gilson P, Harlé A. SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma. *Int J Mol Sci* 2020; **21** [PMID: 32429474 DOI: 10.3390/ijms21103534]

50 **Bartsch D**, Shevlin DW, Tung WS, Kisker O, Wells SA Jr, Goodfellow PJ. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. *Genes Chromosomes Cancer* 1995; **14**: 189-195 [PMID: 8589035 DOI: 10.1002/gcc.2870140306]

51 **Caldas C**, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. *Nat Genet* 1994; **8**: 27-32 [PMID: 7726912 DOI: 10.1038/ng0994-27]

52 **Rozenblum E**, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE. Tumor-suppressive pathways in pancreatic carcinoma. *Cancer Res* 1997; **57**: 1731-1734 [PMID: 9135016]

53 **Bartsch DK**, Sina-Frey M, Lang S, Wild A, Gerdes B, Barth P, Kress R, Grützmann R, Colombo-Benkmann M, Ziegler A, Hahn SA, Rothmund M, Rieder H. CDKN2A germline mutations in familial pancreatic cancer. *Ann Surg* 2002; **236**: 730-737 [PMID: 12454511 DOI: 10.1097/00000658-200212000-00005]

54 **McWilliams RR**, Wieben ED, Rabe KG, Pedersen KS, Wu Y, Sicotte H, Petersen GM. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. *Eur J Hum Genet* 2011; **19**: 472-478 [PMID: 21150883 DOI: 10.1038/ejhg.2010.198]

55 **Goggins M**, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, Bassi C, Carrato A, Farrell J, Fishman EK, Fockens P, Gress TM, van Hooft JE, Hruban RH, Kastrinos F, Klein A, Lennon AM, Lucas A, Park W, Rustgi A, Simeone D, Stoffel E, Vasen HFA, Cahen DL, Canto MI, Bruno M; International Cancer of the Pancreas Screening (CAPS) consortium. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. *Gut* 2020; **69**: 7-17 [PMID: 31672839 DOI: 10.1136/gutjnl-2019-319352]

56 **Ohtsubo K**, Watanabe H, Yamaguchi Y, Hu YX, Motoo Y, Okai T, Sawabu N. Abnormalities of tumor suppressor gene p16 in pancreatic carcinoma: immunohistochemical and genetic findings compared with clinicopathological parameters. *J Gastroenterol* 2003; **38**: 663-671 [PMID: 12898359 DOI: 10.1007/s00535-003-1119-6]

57 **Gerdes B**, Ramaswamy A, Ziegler A, Lang SA, Kersting M, Baumann R, Wild A, Moll R, Rothmund M, Bartsch DK. p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb. *Ann Surg* 2002; **235**: 51-59 [PMID: 11753042 DOI: 10.1097/00000658-200201000-00007]

58 **Qian Y**, Gong Y, Fan Z, Luo G, Huang Q, Deng S, Cheng H, Jin K, Ni Q, Yu X, Liu C. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. *J Hematol Oncol* 2020; **13**: 130 [PMID: 33008426 DOI: 10.1186/s13045-020-00958-3]

59 **Wong W**, Raufi AG, Safyan RA, Bates SE, Manji GA. BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects. *Cancer Manag Res* 2020; **12**: 2731-2742 [PMID: 32368150 DOI: 10.2147/CMAR.S211151]

60 **Golan T**, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL. Maintenance Olaparib for Germline *BRCA*-Mutated Metastatic Pancreatic Cancer. *N Engl J Med* 2019; **381**: 317-327 [PMID: 31157963 DOI: 10.1056/NEJMoa1903387]

61 **Sohal DPS**, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, Garrido-Laguna I, Lau MW, Johnson T, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, Pant S, Shah MA, Sahai V, Uronis HE, Zaidi N, Laheru D. Metastatic Pancreatic Cancer: ASCO Guideline Update. *J Clin Oncol* 2020: JCO2001364 [PMID: 32755482 DOI: 10.1200/JCO.20.01364]

62 **Luchini C**, Brosens LAA, Wood LD, Chatterjee D, Shin JI, Sciammarella C, Fiadone G, Malleo G, Salvia R, Kryklyva V, Piredda ML, Cheng L, Lawlor RT, Adsay V, Scarpa A. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. *Gut* 2021; **70**: 148-156 [PMID: 32350089 DOI: 10.1136/gutjnl-2020-320726]

63 **Hu ZI**, Shia J, Stadler ZK, Varghese AM, Capanu M, Salo-Mullen E, Lowery MA, Diaz LA Jr, Mandelker D, Yu KH, Zervoudakis A, Kelsen DP, Iacobuzio-Donahue CA, Klimstra DS, Saltz LB, Sahin IH, O'Reilly EM. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. *Clin Cancer Res* 2018; **24**: 1326-1336 [PMID: 29367431 DOI: 10.1158/1078-0432.CCR-17-3099]

64 **Bazzichetto C**, Luchini C, Conciatori F, Vaccaro V, Di Cello I, Mattiolo P, Falcone I, Ferretti G, Scarpa A, Cognetti F, Milella M. Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology. *Int J Mol Sci* 2020; **21** [PMID: 33266496 DOI: 10.3390/ijms21228841]

65 **National Comprehensive Cancer Network®**. NCCN guidelines for patients: Pancreatic Cancer. National Comprehensive Cancer Network®, 2019

66 **Pishvaian MJ**, Blais EM, Brody JR, Lyons E, DeArbeloa P, Hendifar A, Mikhail S, Chung V, Sahai V, Sohal DPS, Bellakbira S, Thach D, Rahib L, Madhavan S, Matrisian LM, Petricoin EF 3rd. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. *Lancet Oncol* 2020; **21**: 508-518 [PMID: 32135080 DOI: 10.1016/S1470-2045(20)30074-7]

67 **Peng DF**, Kanai Y, Sawada M, Ushijima S, Hiraoka N, Kitazawa S, Hirohashi S. DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. *Carcinogenesis* 2006; **27**: 1160-1168 [PMID: 16537562 DOI: 10.1093/carcin/bgi361]

68 **Moore MJ**, Feld R, Hedley D, Oza A, Siu LL. A phase II study of temozolomide in advanced untreated pancreatic cancer. *Invest New Drugs* 1998; **16**: 77-79 [PMID: 9740547 DOI: 10.1023/a:1006043332368]

69 **Valero V 3rd**, Saunders TJ, He J, Weiss MJ, Cameron JL, Dholakia A, Wild AT, Shin EJ, Khashab MA, O'Broin-Lennon AM, Ali SZ, Laheru D, Hruban RH, Iacobuzio-Donahue CA, Herman JM, Wolfgang CL. Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing: Implications for Surgical Management. *Ann Surg* 2016; **263**: 153-161 [PMID: 26020105 DOI: 10.1097/SLA.0000000000001156]

70 **Calhoun ES**, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V, Hempen PM, Hilgers W, Yeo CJ, Hruban RH, Kern SE. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. *Am J Pathol* 2003; **163**: 1255-1260 [PMID: 14507635 DOI: 10.1016/S0002-9440(10)63485-2]

71 **Zeng G**, Germinaro M, Micsenyi A, Monga NK, Bell A, Sood A, Malhotra V, Sood N, Midda V, Monga DK, Kokkinakis DM, Monga SP. Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. *Neoplasia* 2006; **8**: 279-289 [PMID: 16756720 DOI: 10.1593/neo.05607]

72 **Doctor A**, Seifert V, Ullrich M, Hauser S, Pietzsch J. Three-Dimensional Cell Culture Systems in Radiopharmaceutical Cancer Research. *Cancers (Basel)* 2020; **12** [PMID: 32993034 DOI: 10.3390/cancers12102765]

73 **Lee JH**, Kim SK, Khawar IA, Jeong SY, Chung S, Kuh HJ. Microfluidic co-culture of pancreatic tumor spheroids with stellate cells as a novel 3D model for investigation of stroma-mediated cell motility and drug resistance. *J Exp Clin Cancer Res* 2018; **37**: 4 [PMID: 29329547 DOI: 10.1186/s13046-017-0654-6]

74 **Finnberg NK**, Gokare P, Lev A, Grivennikov SI, MacFarlane AW 4th, Campbell KS, Winters RM, Kaputa K, Farma JM, Abbas AE, Grasso L, Nicolaides NC, El-Deiry WS. Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures. *Oncotarget* 2017; **8**: 66747-66757 [PMID: 28977993 DOI: 10.18632/oncotarget.19965]

75 **Ehlen L**, Arndt J, Treue D, Bischoff P, Loch FN, Hahn EM, Kotsch K, Klauschen F, Beyer K, Margonis GA, Kreis ME, Kamphues C. Novel methods for *in vitro* modeling of pancreatic cancer reveal important aspects for successful primary cell culture. *BMC Cancer* 2020; **20**: 417 [PMID: 32404074 DOI: 10.1186/s12885-020-06929-8]

76 **Boj SF**, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, Gracanin A, Oni T, Yu KH, van Boxtel R, Huch M, Rivera KD, Wilson JP, Feigin ME, Öhlund D, Handly-Santana A, Ardito-Abraham CM, Ludwig M, Elyada E, Alagesan B, Biffi G, Yordanov GN, Delcuze B, Creighton B, Wright K, Park Y, Morsink FH, Molenaar IQ, Borel Rinkes IH, Cuppen E, Hao Y, Jin Y, Nijman IJ, Iacobuzio-Donahue C, Leach SD, Pappin DJ, Hammell M, Klimstra DS, Basturk O, Hruban RH, Offerhaus GJ, Vries RG, Clevers H, Tuveson DA. Organoid models of human and mouse ductal pancreatic cancer. *Cell* 2015; **160**: 324-338 [PMID: 25557080 DOI: 10.1016/j.cell.2014.12.021]

77 **Baker LA**, Tiriac H, Tuveson DA. Generation and Culture of Human Pancreatic Ductal Adenocarcinoma Organoids from Resected Tumor Specimens. *Methods Mol Biol* 2019; **1882**: 97-115 [PMID: 30378047 DOI: 10.1007/978-1-4939-8879-2\_9]

78 **Drost J**, Clevers H. Organoids in cancer research. *Nat Rev Cancer* 2018; **18**: 407-418 [PMID: 29692415 DOI: 10.1038/s41568-018-0007-6]

79 **Kanda M**, Matthaei H, Wu J, Hong SM, Yu J, Borges M, Hruban RH, Maitra A, Kinzler K, Vogelstein B, Goggins M. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. *Gastroenterology* 2012; **142**: 730-733.e9 [PMID: 22226782 DOI: 10.1053/j.gastro.2011.12.042]

80 **Guerra C**, Schuhmacher AJ, Cañamero M, Grippo PJ, Verdaguer L, Pérez-Gallego L, Dubus P, Sandgren EP, Barbacid M. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. *Cancer Cell* 2007; **11**: 291-302 [PMID: 17349585 DOI: 10.1016/j.ccr.2007.01.012]

81 **Hingorani SR**, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowy AM, Tuveson DA. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer Cell* 2003; **4**: 437-450 [PMID: 14706336 DOI: 10.1016/s1535-6108(03)00309-x]

82 **Pylayeva-Gupta Y**, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. *Nat Rev Cancer* 2011; **11**: 761-774 [PMID: 21993244 DOI: 10.1038/nrc3106]

83 **Seidler B**, Schmidt A, Mayr U, Nakhai H, Schmid RM, Schneider G, Saur D. A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown *in vivo* by using avian retroviral vectors. *Proc Natl Acad Sci U S A* 2008; **105**: 10137-10142 [PMID: 18621715 DOI: 10.1073/pnas.0800487105]

84 **Nikiforova MN**, Khalid A, Fasanella KE, McGrath KM, Brand RE, Chennat JS, Slivka A, Zeh HJ, Zureikat AH, Krasinskas AM, Ohori NP, Schoedel KE, Navina S, Mantha GS, Pai RK, Singhi AD. Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts. *Mod Pathol* 2013; **26**: 1478-1487 [PMID: 23743931 DOI: 10.1038/modpathol.2013.91]

85 **Molin MD**, Matthaei H, Wu J, Blackford A, Debeljak M, Rezaee N, Wolfgang CL, Butturini G, Salvia R, Bassi C, Goggins MG, Kinzler KW, Vogelstein B, Eshleman JR, Hruban RH, Maitra A. Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas. *Ann Surg Oncol* 2013; **20**: 3802-3808 [PMID: 23846778 DOI: 10.1245/s10434-013-3096-1]

86 **Khalid A**, Zahid M, Finkelstein SD, LeBlanc JK, Kaushik N, Ahmad N, Brugge WR, Edmundowicz SA, Hawes RH, McGrath KM. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. *Gastrointest Endosc* 2009; **69**: 1095-1102 [PMID: 19152896 DOI: 10.1016/j.gie.2008.07.033]

87 **Al-Haddad M**, DeWitt J, Sherman S, Schmidt CM, LeBlanc JK, McHenry L, Coté G, El Chafic AH, Luz L, Stuart JS, Johnson CS, Klochan C, Imperiale TF. Performance characteristics of molecular (DNA) analysis for the diagnosis of mucinous pancreatic cysts. *Gastrointest Endosc* 2014; **79**: 79-87 [PMID: 23845445 DOI: 10.1016/j.gie.2013.05.026]

88 **Kuboki Y**, Shimizu K, Hatori T, Yamamoto M, Shibata N, Shiratori K, Furukawa T. Molecular biomarkers for progression of intraductal papillary mucinous neoplasm of the pancreas. *Pancreas* 2015; **44**: 227-235 [PMID: 25423558 DOI: 10.1097/MPA.0000000000000253]

89 **Komatsu H**, Tanji E, Sakata N, Aoki T, Motoi F, Naitoh T, Katayose Y, Egawa S, Unno M, Furukawa T. A GNAS mutation found in pancreatic intraductal papillary mucinous neoplasms induces drastic alterations of gene expression profiles with upregulation of mucin genes. *PLoS One* 2014; **9**: e87875 [PMID: 24498386 DOI: 10.1371/journal.pone.0087875]

90 **Amato E**, Molin MD, Mafficini A, Yu J, Malleo G, Rusev B, Fassan M, Antonello D, Sadakari Y, Castelli P, Zamboni G, Maitra A, Salvia R, Hruban RH, Bassi C, Capelli P, Lawlor RT, Goggins M, Scarpa A. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. *J Pathol* 2014; **233**: 217-227 [PMID: 24604757 DOI: 10.1002/path.4344]

91 **Rosenbaum MW**, Jones M, Dudley JC, Le LP, Iafrate AJ, Pitman MB. Next-generation sequencing adds value to the preoperative diagnosis of pancreatic cysts. *Cancer Cytopathol* 2017; **125**: 41-47 [PMID: 27647802 DOI: 10.1002/cncy.21775]

92 **Wu J**, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, Wood LD, Eshleman JR, Goggins MG, Wolfgang CL, Canto MI, Schulick RD, Edil BH, Choti MA, Adsay V, Klimstra DS, Offerhaus GJ, Klein AP, Kopelovich L, Carter H, Karchin R, Allen PJ, Schmidt CM, Naito Y, Diaz LA Jr, Kinzler KW, Papadopoulos N, Hruban RH, Vogelstein B. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. *Proc Natl Acad Sci U S A* 2011; **108**: 21188-21193 [PMID: 22158988 DOI: 10.1073/pnas.1118046108]

93 **Furukawa T**, Kuboki Y, Tanji E, Yoshida S, Hatori T, Yamamoto M, Shibata N, Shimizu K, Kamatani N, Shiratori K. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. *Sci Rep* 2011; **1**: 161 [PMID: 22355676 DOI: 10.1038/srep00161]

94 **Singhi AD**, Nikiforova MN, Fasanella KE, McGrath KM, Pai RK, Ohori NP, Bartholow TL, Brand RE, Chennat JS, Lu X, Papachristou GI, Slivka A, Zeh HJ, Zureikat AH, Lee KK, Tsung A, Mantha GS, Khalid A. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts. *Clin Cancer Res* 2014; **20**: 4381-4389 [PMID: 24938521 DOI: 10.1158/1078-0432.CCR-14-0513]

95 **Wu J**, Matthaei H, Maitra A, Dal Molin M, Wood LD, Eshleman JR, Goggins M, Canto MI, Schulick RD, Edil BH, Wolfgang CL, Klein AP, Diaz LA Jr, Allen PJ, Schmidt CM, Kinzler KW, Papadopoulos N, Hruban RH, Vogelstein B. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. *Sci Transl Med* 2011; **3**: 92ra66 [PMID: 21775669 DOI: 10.1126/scitranslmed.3002543]

96 **Lee JH**, Kim Y, Choi JW, Kim YS. KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. *Springerplus* 2016; **5**: 1172 [PMID: 27512631 DOI: 10.1186/s40064-016-2847-4]

97 **Abe T**, Fukushima N, Brune K, Boehm C, Sato N, Matsubayashi H, Canto M, Petersen GM, Hruban RH, Goggins M. Genome-wide allelotypes of familial pancreatic adenocarcinomas and familial and sporadic intraductal papillary mucinous neoplasms. *Clin Cancer Res* 2007; **13**: 6019-6025 [PMID: 17947463 DOI: 10.1158/1078-0432.CCR-07-0471]

98 **Su GH**, Hruban RH, Bansal RK, Bova GS, Tang DJ, Shekher MC, Westerman AM, Entius MM, Goggins M, Yeo CJ, Kern SE. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. *Am J Pathol* 1999; **154**: 1835-1840 [PMID: 10362809 DOI: 10.1016/S0002-9440(10)65440-5]

99 **Sato N**, Rosty C, Jansen M, Fukushima N, Ueki T, Yeo CJ, Cameron JL, Iacobuzio-Donahue CA, Hruban RH, Goggins M. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. *Am J Pathol* 2001; **159**: 2017-2022 [PMID: 11733352 DOI: 10.1016/S0002-9440(10)63053-2]

100 **Singhi AD**, McGrath K, Brand RE, Khalid A, Zeh HJ, Chennat JS, Fasanella KE, Papachristou GI, Slivka A, Bartlett DL, Dasyam AK, Hogg M, Lee KK, Marsh JW, Monaco SE, Ohori NP, Pingpank JF, Tsung A, Zureikat AH, Wald AI, Nikiforova MN. Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia. *Gut* 2018; **67**: 2131-2141 [PMID: 28970292 DOI: 10.1136/gutjnl-2016-313586]

101 **Yoshizawa K**, Nagai H, Sakurai S, Hironaka M, Morinaga S, Saitoh K, Fukayama M. Clonality and K-ras mutation analyses of epithelia in intraductal papillary mucinous tumor and mucinous cystic tumor of the pancreas. *Virchows Arch* 2002; **441**: 437-443 [PMID: 12447672 DOI: 10.1007/s00428-002-0645-6]

102 **Kim SG**, Wu TT, Lee JH, Yun YK, Issa JP, Hamilton SR, Rashid A. Comparison of epigenetic and genetic alterations in mucinous cystic neoplasm and serous microcystic adenoma of pancreas. *Mod Pathol* 2003; **16**: 1086-1094 [PMID: 14614047 DOI: 10.1097/01.MP.0000094088.37888.A6]

103 **Jimenez RE**, Warshaw AL, Z'graggen K, Hartwig W, Taylor DZ, Compton CC, Fernández-del Castillo C. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. *Ann Surg* 1999; **230**: 501-9; discussion 509-11 [PMID: 10522720 DOI: 10.1097/00000658-199910000-00006]

104 **Garcia-Carracedo D**, Chen ZM, Qiu W, Huang AS, Tang SM, Hruban RH, Su GH. PIK3CA mutations in mucinous cystic neoplasms of the pancreas. *Pancreas* 2014; **43**: 245-249 [PMID: 24518503 DOI: 10.1097/MPA.0000000000000034]

105 **Izeradjene K**, Combs C, Best M, Gopinathan A, Wagner A, Grady WM, Deng CX, Hruban RH, Adsay NV, Tuveson DA, Hingorani SR. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. *Cancer Cell* 2007; **11**: 229-243 [PMID: 17349581 DOI: 10.1016/j.ccr.2007.01.017]

106 **Bardeesy N**, Cheng KH, Berger JH, Chu GC, Pahler J, Olson P, Hezel AF, Horner J, Lauwers GY, Hanahan D, DePinho RA. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. *Genes Dev* 2006; **20**: 3130-3146 [PMID: 17114584 DOI: 10.1101/gad.1478706]

107 **Springer S**, Wang Y, Dal Molin M, Masica DL, Jiao Y, Kinde I, Blackford A, Raman SP, Wolfgang CL, Tomita T, Niknafs N, Douville C, Ptak J, Dobbyn L, Allen PJ, Klimstra DS, Schattner MA, Schmidt CM, Yip-Schneider M, Cummings OW, Brand RE, Zeh HJ, Singhi AD, Scarpa A, Salvia R, Malleo G, Zamboni G, Falconi M, Jang JY, Kim SW, Kwon W, Hong SM, Song KB, Kim SC, Swan N, Murphy J, Geoghegan J, Brugge W, Fernandez-Del Castillo C, Mino-Kenudson M, Schulick R, Edil BH, Adsay V, Paulino J, van Hooft J, Yachida S, Nara S, Hiraoka N, Yamao K, Hijioka S, van der Merwe S, Goggins M, Canto MI, Ahuja N, Hirose K, Makary M, Weiss MJ, Cameron J, Pittman M, Eshleman JR, Diaz LA Jr, Papadopoulos N, Kinzler KW, Karchin R, Hruban RH, Vogelstein B, Lennon AM. A combination of molecular markers and clinical features improve the classification of pancreatic cysts. *Gastroenterology* 2015; **149**: 1501-1510 [PMID: 26253305 DOI: 10.1053/j.gastro.2015.07.041]

108 **Wood LD**, Hruban RH. Pathology and molecular genetics of pancreatic neoplasms. *Cancer J* 2012; **18**: 492-501 [PMID: 23187835 DOI: 10.1097/PPO.0b013e31827459b6]

109 **Charville GW**, Kao CS. Serous Neoplasms of the Pancreas: A Comprehensive Review. *Arch Pathol Lab Med* 2018; **142**: 1134-1140 [PMID: 30141993 DOI: 10.5858/arpa.2017-0195-RS]

110 **Nelson WJ**, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. *Science* 2004; **303**: 1483-1487 [PMID: 15001769 DOI: 10.1126/science.1094291]

111 **Rubinfeld B**, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. *Science* 1997; **275**: 1790-1792 [PMID: 9065403 DOI: 10.1126/science.275.5307.1790]

112 **Tanaka Y**, Kato K, Notohara K, Hojo H, Ijiri R, Miyake T, Nagahara N, Sasaki F, Kitagawa N, Nakatani Y, Kobayashi Y. Frequent beta-catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm. *Cancer Res* 2001; **61**: 8401-8404 [PMID: 11731417]

113 **Abraham SC**, Klimstra DS, Wilentz RE, Yeo CJ, Conlon K, Brennan M, Cameron JL, Wu TT, Hruban RH. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. *Am J Pathol* 2002; **160**: 1361-1369 [PMID: 11943721 DOI: 10.1016/s0002-9440(10)62563-1]

114 **Kubota Y**, Kawakami H, Natsuizaka M, Kawakubo K, Marukawa K, Kudo T, Abe Y, Kubo K, Kuwatani M, Hatanaka Y, Mitsuhashi T, Matsuno Y, Sakamoto N. CTNNB1 mutational analysis of solid-pseudopapillary neoplasms of the pancreas using endoscopic ultrasound-guided fine-needle aspiration and next-generation deep sequencing. *J Gastroenterol* 2015; **50**: 203-210 [PMID: 24700283 DOI: 10.1007/s00535-014-0954-y]

115 **Kempski HM**, Austin N, Chatters SJ, Toomey SM, Chalker J, Anderson J, Sebire NJ. Previously unidentified complex cytogenetic changes found in a pediatric case of solid-pseudopapillary neoplasm of the pancreas. *Cancer Genet Cytogenet* 2006; **164**: 54-60 [PMID: 16364763 DOI: 10.1016/j.cancergencyto.2005.06.017]

116 **Selenica P**, Raj N, Kumar R, Brown DN, Arqués O, Reidy D, Klimstra D, Snuderl M, Serrano J, Palmer HG, Weigelt B, Reis-Filho JS, Scaltriti M. Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway. *Mol Oncol* 2019; **13**: 1684-1692 [PMID: 30972907 DOI: 10.1002/1878-0261.12490]

117 **Vijayvergia N**, Boland PM, Handorf E, Gustafson KS, Gong Y, Cooper HS, Sheriff F, Astsaturov I, Cohen SJ, Engstrom PF. Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study. *Br J Cancer* 2016; **115**: 564-570 [PMID: 27482646 DOI: 10.1038/bjc.2016.229]

118 **Jiao Y**, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA Jr, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. *Science* 2011; **331**: 1199-1203 [PMID: 21252315 DOI: 10.1126/science.1200609]

119 **Corbo V**, Dalai I, Scardoni M, Barbi S, Beghelli S, Bersani S, Albarello L, Doglioni C, Schott C, Capelli P, Chilosi M, Boninsegna L, Becker KF, Falconi M, Scarpa A. MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. *Endocr Relat Cancer* 2010; **17**: 771-783 [PMID: 20566584 DOI: 10.1677/ERC-10-0028]

120 **Missiaglia E**, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G, Pederzoli P, Croce CM, Scarpa A. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. *J Clin Oncol* 2010; **28**: 245-255 [PMID: 19917848 DOI: 10.1200/JCO.2008.21.5988]

121 **Schmitt AM**, Schmid S, Rudolph T, Anlauf M, Prinz C, Klöppel G, Moch H, Heitz PU, Komminoth P, Perren A. VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors. *Endocr Relat Cancer* 2009; **16**: 1219-1227 [PMID: 19690016 DOI: 10.1677/ERC-08-0297]

122 **Scarpa A**, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, Lawlor RT, Johns AL, Miller DK, Mafficini A, Rusev B, Scardoni M, Antonello D, Barbi S, Sikora KO, Cingarlini S, Vicentini C, McKay S, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, McLean S, Nourse C, Nourbakhsh E, Wilson PJ, Anderson MJ, Fink JL, Newell F, Waddell N, Holmes O, Kazakoff SH, Leonard C, Wood S, Xu Q, Nagaraj SH, Amato E, Dalai I, Bersani S, Cataldo I, Dei Tos AP, Capelli P, Davì MV, Landoni L, Malpaga A, Miotto M, Whitehall VL, Leggett BA, Harris JL, Harris J, Jones MD, Humphris J, Chantrill LA, Chin V, Nagrial AM, Pajic M, Scarlett CJ, Pinho A, Rooman I, Toon C, Wu J, Pinese M, Cowley M, Barbour A, Mawson A, Humphrey ES, Colvin EK, Chou A, Lovell JA, Jamieson NB, Duthie F, Gingras MC, Fisher WE, Dagg RA, Lau LM, Lee M, Pickett HA, Reddel RR, Samra JS, Kench JG, Merrett ND, Epari K, Nguyen NQ, Zeps N, Falconi M, Simbolo M, Butturini G, Van Buren G, Partelli S, Fassan M; Australian Pancreatic Cancer Genome Initiative, Khanna KK, Gill AJ, Wheeler DA, Gibbs RA, Musgrove EA, Bassi C, Tortora G, Pederzoli P, Pearson JV, Waddell N, Biankin AV, Grimmond SM. Whole-genome landscape of pancreatic neuroendocrine tumours. *Nature* 2017; **543**: 65-71 [PMID: 28199314 DOI: 10.1038/nature21063]

123 **Rigaud G**, Moore PS, Zamboni G, Orlandini S, Taruscio D, Paradisi S, Lemoine NR, Klöppel G, Scarpa A. Allelotype of pancreatic acinar cell carcinoma. *Int J Cancer* 2000; **88**: 772-777 [PMID: 11072247 DOI: 10.1002/1097-0215(20001201)88:5<772::aid-ijc14>3.0.co;2-w]

124 **Jäkel C**, Bergmann F, Toth R, Assenov Y, van der Duin D, Strobel O, Hank T, Klöppel G, Dorrell C, Grompe M, Moss J, Dor Y, Schirmacher P, Plass C, Popanda O, Schmezer P. Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability. *Nat Commun* 2017; **8**: 1323 [PMID: 29109526 DOI: 10.1038/s41467-017-01118-x]

125 **La Rosa S**, Bernasconi B, Frattini M, Tibiletti MG, Molinari F, Furlan D, Sahnane N, Vanoli A, Albarello L, Zhang L, Notohara K, Casnedi S, Chenard MP, Adsay V, Asioli S, Capella C, Sessa F. TP53 alterations in pancreatic acinar cell carcinoma: new insights into the molecular pathology of this rare cancer. *Virchows Arch* 2016; **468**: 289-296 [PMID: 26586531 DOI: 10.1007/s00428-015-1882-9]

126 **Jiao Y**, Yonescu R, Offerhaus GJ, Klimstra DS, Maitra A, Eshleman JR, Herman JG, Poh W, Pelosof L, Wolfgang CL, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N, Wood LD. Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. *J Pathol* 2014; **232**: 428-435 [PMID: 24293293 DOI: 10.1002/path.4310]

127 **Thompson ED**, Wood LD. Pancreatic Neoplasms With Acinar Differentiation: A Review of Pathologic and Molecular Features. *Arch Pathol Lab Med* 2020; **144**: 808-815 [PMID: 31869246 DOI: 10.5858/arpa.2019-0472-RA]

128 **Liu W**, Shia J, Gönen M, Lowery MA, O'Reilly EM, Klimstra DS. DNA mismatch repair abnormalities in acinar cell carcinoma of the pancreas: frequency and clinical significance. *Pancreas* 2014; **43**: 1264-1270 [PMID: 25058881 DOI: 10.1097/MPA.0000000000000190]

129 **Ducreux M**, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, Arnold D; ESMO Guidelines Committee. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2015; **26 Suppl 5**: v56-v68 [PMID: 26314780 DOI: 10.1093/annonc/mdv295]

130 **Hong SK**, Loren DE, Rogart JN, Siddiqui AA, Sendecki JA, Bibbo M, Coben RM, Meckes DP, Kowalski TE. Targeted cyst wall puncture and aspiration during EUS-FNA increases the diagnostic yield of premalignant and malignant pancreatic cysts. *Gastrointest Endosc* 2012; **75**: 775-782 [PMID: 22317883 DOI: 10.1016/j.gie.2011.12.015]

131 **Dumonceau JM**, Polkowski M, Larghi A, Vilmann P, Giovannini M, Frossard JL, Heresbach D, Pujol B, Fernández-Esparrach G, Vazquez-Sequeiros E, Ginès A; European Society of Gastrointestinal Endoscopy. Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. *Endoscopy* 2011; **43**: 897-912 [PMID: 21842456 DOI: 10.1055/s-0030-1256754]

132 **Jenssen C**, Hocke M, Fusaroli P, Gilja OH, Buscarini E, Havre RF, Ignee A, Saftoiu A, Vilmann P, Burmester E, Nolsøe CP, Nürnberg D, D'Onofrio M, Lorentzen T, Piscaglia F, Sidhu PS, Dietrich CF. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part IV - EUS-guided Interventions: General aspects and EUS-guided sampling (Long Version). *Ultraschall Med* 2016; **37**: E33-E76 [PMID: 26515966 DOI: 10.1055/s-0035-1553785]

133 **Varadarajulu S**, Fockens P, Hawes RH. Best practices in endoscopic ultrasound-guided fine-needle aspiration. *Clin Gastroenterol Hepatol* 2012; **10**: 697-703 [PMID: 22475740 DOI: 10.1016/j.cgh.2012.03.017]

134 **Pishvaian MJ**, Bender RJ, Halverson D, Rahib L, Hendifar AE, Mikhail S, Chung V, Picozzi VJ, Sohal D, Blais EM, Mason K, Lyons EE, Matrisian LM, Brody JR, Madhavan S, Petricoin EF 3rd. Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. *Clin Cancer Res* 2018; **24**: 5018-5027 [PMID: 29954777 DOI: 10.1158/1078-0432.CCR-18-0531]

135 **Ko SH**, Pyo JS, Son BK, Lee HY, Oh IW, Chung KH. Comparison between Conventional Smear and Liquid-Based Preparation in Endoscopic Ultrasonography-Fine Needle Aspiration Cytology of Pancreatic Lesions. *Diagnostics (Basel)* 2020; **10** [PMID: 32397572 DOI: 10.3390/diagnostics10050293]

136 **Fabbri C**, Fornelli A, Fuccio L, Giovanelli S, Tarantino I, Antonini F, Liotta R, Frazzoni L, Gusella P, La Marca M, Barresi L, Macarri G, Traina M, De Biase D, Fiorino S, Jovine E, Larghi A, Cennamo V. High diagnostic adequacy and accuracy of the new 20G procore needle for EUS-guided tissue acquisition: Results of a large multicentre retrospective study. *Endosc Ultrasound* 2019; **8**: 261-268 [PMID: 31115386 DOI: 10.4103/eus.eus\_14\_19]

137 **Sho S**, Court CM, Kim S, Braxton DR, Hou S, Muthusamy VR, Watson RR, Sedarat A, Tseng HR, Tomlinson JS. Digital PCR Improves Mutation Analysis in Pancreas Fine Needle Aspiration Biopsy Specimens. *PLoS One* 2017; **12**: e0170897 [PMID: 28125707 DOI: 10.1371/journal.pone.0170897]

138 **de Biase D**, Visani M, Acquaviva G, Fornelli A, Masetti M, Fabbri C, Pession A, Tallini G. The Role of Next-Generation Sequencing in the Cytologic Diagnosis of Pancreatic Lesions. *Arch Pathol Lab Med* 2018; **142**: 458-464 [PMID: 29565213 DOI: 10.5858/arpa.2017-0215-RA]

139 **de Biase D**, Fassan M, Malapelle U. Next-Generation Sequencing in Tumor Diagnosis and Treatment. *Diagnostics (Basel)* 2020; **10** [PMID: 33212911 DOI: 10.3390/diagnostics10110962]

140 **Mosele F**, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. *Ann Oncol* 2020; **31**: 1491-1505 [PMID: 32853681 DOI: 10.1016/j.annonc.2020.07.014]

**Footnotes**

**Conflict-of-interest statement:** Authors have nothing to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** January 17, 2021

**First decision:** February 9, 2021

**Article in press:** April 14, 2021

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Aykan NF, Chin YK, Labori KJ, Shiryajev YN **S-Editor:** Gao CC **L-Editor:** Webster JR **P-Editor:** Ma YJ

**Table 1 Main genetic alterations detectable in pancreatic ductal adenocarcinoma**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Type of pancreatic lesion** | **Genetic alteration** | **Reported frequency (%)** | **Type of alterations** | **Role in clinical practice** |
| PDAC | *KRAS* | 70-90 | Point mutations | Diagnostic/prognostic |
| *TP53* | 50-75 | Point mutations/LOH | Prognostic |
| *CDKN2A/p16* | 90-98 | Point mutations/LOH | Prognostic/genetic surveillance |
| *SMAD4* | 40-60 | Point mutations/LOH | Prognostic |
| *BRCA1/2* | 5-10 | Point mutations | Predictive/genetic surveillance |
| *NTRK1-3* | < 1 | Gene fusions | Predictive |
| *MSI* | < 2 | LOF | Predictive |

The percentages quoted are estimated from the literature cited in the paper. Diagnostic role appears mainly in preoperative material. In bold those markers recommended for clinical practice by National Comprehensive Cancer Network 2019 guidelines. PDAC: Pancreatic ductal adenocarcinoma; LOH: Loss of heterozygosity.

**Table 2 Main genetic alterations detectable in cystic pancreatic lesions**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Type of pancreatic lesion** | **Genetic alteration** | **Reported frequency (%)** | **Type of alterations** | **Role in clinical practice** |
| IPMN | *KRAS* | 90 | Point mutations | Diagnostic |
| *TP53* | 10 | Point mutations/LOH | Prognostic |
| *GNAS* | 40-60 | Point mutations | Diagnostic |
| *RNF43* | 25 | Point mutations/LOH | Diagnostic |
| MCN | *KRAS* | 0-25% (LG)  50-90% (HG) | Point mutations | Diagnostic |
| *CDKN2A/p16* | 0-10 (LG); 50 (HG) | Point mutations/LOH | Prognostic |
| *TP53* | 0 (LG); 20-50 (HG) | Point mutations/LOH | Prognostic |
| SCN | *VHL* | 40-60 | Point mutations/LOH | Diagnostic |

The percentages quoted are estimated from the literature cited in the paper. Diagnostic role appears mainly in preoperative material. IPMN: Intraductal papillary mucinous neoplasms; MCN: Mucinous cystic neoplasia; LG: Low-grade mucinous cystic neoplasia; HG: High-grade mucinous cystic neoplasia; SCN: Serous cystic neoplasm; LOH: Loss of heterozygosity.

**Table 3 Main genetic alterations detectable in other pancreatic tumors**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Type of pancreatic lesion** | **Genetic alteration** | **Reported frequency (%)** | **Type of alterations** | **Role in clinical practice** |
| SPN | *CTNNB1* | 90-100 | Point mutations | Diagnostic |
| PanNET | *MEN1* | 70 | Point mutations/LOH | Diagnostic/prognostic |
| *VHL* | 25 | Point mutations/LOH | Diagnostic |
| AAC | *CTNNB1* | 5-25 | Point mutations  LOF | Diagnostic |
| *MSI* | 5-15 | LOF | Predictive? |

The percentages quoted are estimated from the literature cited in the paper. Diagnostic role appears mainly in preoperative material. SPN: Solid pseudopapillary neoplasm; PanNET: Pancreatic neuroendocrine tumor; AAC: Acinic adenocarcinoma; LOH: Loss of heterozygosity; LOF: Loss of function.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**